Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Megan M., Clemons, Mark, Stober, Carol, Jeong, Ahwon, Vandermeer, Lisa, Mates, Mihaela, Blanchette, Phillip, Joy, Anil Abraham, Aseyev, Olexiy, Pond, Gregory, Fergusson, Dean, Ng, Terry L., Thavorn, Kednapa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/
https://www.ncbi.nlm.nih.gov/pubmed/34068083
http://dx.doi.org/10.3390/curroncol28030171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/
https://www.ncbi.nlm.nih.gov/pubmed/34068083
http://dx.doi.org/10.3390/curroncol28030171

Ejemplares similares